Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer

Conclusion131I-Atezolizumab can be used as a CLI agent for screening PD-L1 expression levels. It may be used as a radioimmunotherapy drug target for PD- L1 overexpressing tumors.
Source: EJNMMI Research - Category: Radiology Source Type: research